Detectability of hepatitis B virus DNA in peripheral blood mononuclear cells following long-term nucleos(t)ide analogue therapy-induced sustained viral suppression

Key Points

• HBV DNA can persist in PBMCs despite long-term nucleos(t)ide analogue therapy, indicating a potential risk.
• Key evidence shows a relationship between pretreatment HBeAg positivity and elevated qHBsAg after treatment.
• Analysis involves examining peripheral blood mononuclear cells to determine HBV DNA detectability after therapy.
• Monitoring HBV DNA reservoirs is crucial for effective chronic hepatitis B management, pointing to additional treatment needs.